Japan-based medtech firm Olympus Corporation has signed a definitive agreement to acquire BioProtect, a medical device manufacturer aiming to advance cancer care through innovative spacing solutions. This marks an important expansion of Olympus' contributions to oncology and urology in line with its corporate strategy to accelerate cutting-edge technologies and focus on patient safety and outcomes.
The $270 million acquisition, with certain amounts held in escrow for a period dependent on uninterrupted operation of the business, is expected to be completed by the end of the second quarter of calendar year 2026, subject to customary closing conditions.
BioProtect develops implant technologies that contribute to improving prostate cancer care and enhancing patients' quality of life. Its flagship Balloon Spacer system is designed to provide consistent spacing between the prostate and other critical structures, protecting healthy tissues during prostate cancer radiation therapies. After treatment, the implant naturally biodegrades.
Following its commercial introduction in 2023, the Balloon Spacer has been used in more than 11,000 procedures worldwide, with studies indicating the device's contribution to preserving gastrointestinal, urinary and sexual functions for patients.
For Olympus, the acquisition of BioProtect aligns with its strategic pillar of Innovation-driven Growth as a global MedTech leader. With prostate cancer as the second most diagnosed form of cancer amongst men worldwide, the acquisition underscores the company's commitment to solutions that address unmet medical needs in cancer treatment.
